中国药物经济学2025，Vol.20Issue(6)：45-49,67,6.DOI:10.12010/j.issn.1673-5846.2025.06.007
聚乙二醇化重组人粒细胞刺激因子注射液的经济学评价
Economic Evaluation of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection
摘要
Abstract
Objective To evaluate the cost-effectiveness of three drugs,PEGylated recombinant human granulocyte stimulating factor(PEG-rhG-CSF)injection,Mecapegfilgrastim injection and recombinant human granulocyte stimulating factor(rhG-CSF)injection,in the prevention and treatment of neutropenia after chemotherapy in tumor patients.Methods The case data of neutropenia after tumor chemotherapy treated with PEG-rhG-CSF injection,Mecapegfilgrastim and rhG-CSF injection were extracted from the hospital information system of Qingyuan People's Hospital(HIS)from January 1,2019 to July 31,2022.Taking the percentage of cases where grade 1～4 neutropenia did not occur after medication to the total number of cases as the effective rate,the cost-effectiveness of the drug treatment regimens in the three groups was compared,and a sensitivity analysis was conducted.Results The effective rates of the PEG-rhG-CSF group,the Mecapegfilgrastim group and the rhG-CSF group were 91.15%(381/418),88.29%(294/333)and 69.63%(282/405),respectively.The drug costs of the PEG-rhG-CSF group,the Mecapegfilgrastim group and the rhG-CSF group were(1 994.93±396.72)yuan,(2 711.21±20.44)yuan and(143.68±124.95)yuan respectively.The total costs were(2 074.45±394.75)yuan,(2 800.01±46.30)yuan and(177.52±136.29)yuan respectively.The percentage without neutropenia was used as the effect indicator to compare the incremental cost-effectiveness ratio(ICER)of each drug group.Compared with the rhG-CSF group,the ICers of the PEG-rhG-CSF group and the Mecapegfilgrastim group were 8 814.73 and 14 054.07,respectively.The ICER of both the PEG-rhG-CSF group and the Mecapegfilgrastim group was lower than twice the per capita gross domestic product(GDP)in 2022.However,PEG-rhG-CSF has a lower cost and a higher efficiency.The results of the sensitivity analysis show that assuming the price reduction of each drug is 30%and the effective rate remains unchanged,the calculated results are consistent with those before the price adjustment,,indicating that the cost-effectiveness analysis results are robust.Conclusion PEG-rhG-CSF injection is economical for the prevention and treatment of neutropenia in tumor patients after chemotherapy.关键词
聚乙二醇化重组人粒细胞刺激因子/中性粒细胞减少症/发热性中性粒细胞减少症/成本-效果分析Key words
PEG-rhG-CSF/Neutropenia/Febrile neutropenia/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
林杰茹,常惠礼,冯汨,王馨,汤锐明..聚乙二醇化重组人粒细胞刺激因子注射液的经济学评价[J].中国药物经济学,2025,20(6):45-49,67,6.基金项目
广东省颐养健康慈善基金(JZ2022015) （JZ2022015）
